Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open multicenter study of intensive chemotherapy for Ewing sarcoma
2009-016027-62Phase 2Completed
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Nov 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin, vincristine, ifosfamide, etoposide, cyclophosphamide and 2 more in Ewing sarcoma (2 arms), sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: 3-year disease-free survival, Objective response rate and 2 more. Started Nov 2009; status: completed.
02
Drugs
doxorubicinvincristineifosfamideetoposidecyclophosphamide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on 2009-016027-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016027-62.